CLINICAL_TRIALS
ClinicalTrials.gov record update
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05726864
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:12.747310+00:00
- Published At
- 2026-03-17T00:00:00+00:00
- Record Updated At
- 2026-03-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "KRAS G12D", "KRAS G12R", "KRAS G12V", "KRAS G12A", "KRAS G12C", "KRAS G12S", "KRAS G13D", "NRAS G12D", "NRAS G12R", "NRAS G12V", "NRAS G12C", "NRAS G12S"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-17"- protocolSection.identificationModule.nctId
"NCT05726864"- protocolSection.identificationModule.officialTitle
"First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.